Since the inhibition of hGDH1 by shRNA or specific inhibitors impairs cell proliferation and tumor growth [15,16], to investigate how this metabolic pathway contributes to HCC progression may represent a new therapeutic strategy minding hGDH as a pharmacological target. This evidence concerns the gene GLUD1 and neoplasm.